id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-002630-5616n73p	Dargahi, Narges	Multiple Sclerosis: Immunopathology and Treatment Update	2017-07-07		.txt	text/plain	11316	561	47	We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS. Based on Phase III human clinical trials in patients with RRMS (TRANSFORMS, FREEDOMS and FREEDOMS II), fingolimod was more effective compared to first line treatment IFNβ-1a and placebo, in reducing the frequency of flare-ups (clinical exacerbations), disability progression, MRI outcome measures, including brain volume loss and was associated with clearly identified adverse events [103, 136, 137] . Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (mbp(87-99)) epitope elicits a th1 polarized response by t cells isolated from multiple sclerosis patients: Implications in triggering disease	./cache/cord-002630-5616n73p.txt	./txt/cord-002630-5616n73p.txt